Blauvelt A, et al. - Authors evaluated the T-cell-dependent and -independent humoral responses to tetanus and meningococcal vaccines, IgE seroconversion to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination, and dupilumab efficacy and safety. In this randomized, double-blinded, placebo-controlled study, adults with moderate-to-severe atopic dermatitis (AD) received dupilumab (300 mg) or placebo weekly for 16 weeks, and single doses of Tdap and quadrivalent meningococcal polysaccharide vaccines at Week 12. Findings suggested that dupilumab demonstrated a satisfactory safety profile. Compared to placebo, dupilumab significantly decreased IgE and improved measures of AD severity without affecting responses to the vaccines studied. With dupilumab, injection-site reactions and conjunctivitis were more commonly noted; with placebo, AD exacerbations were more frequent.